Nanostructured lipid carrier based composition of poorly soluble Anti-fungal agent
Patent Information
- Application Number
- IN202221004921
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2022-01-28
- Publication Date
- 2026-10-26
- Estimated Expiration
- 2042-01-28
AI Technical Summary
Poorly soluble anti-fungal drug substances like posaconazole face challenges in bioavailability and patient compliance due to low solubility and large tablet sizes, leading to reduced absorption and increased pill burden, which affects treatment efficacy and compliance.
Development of a stable pharmaceutical composition using nanostructured lipid carriers (NLCs) and solid lipid nanoparticles (SLNs) that enhance the bioavailability and solubility of posaconazole, allowing for a smaller, more manageable dosage form that can be easily swallowed, reducing the daily dose and pill burden.
The nanostructured lipid carrier-based composition improves the bioavailability and solubility of posaconazole, leading to enhanced absorption, reduced side effects, and improved patient compliance by reducing the necessary daily dose and pill burden, while maintaining stability and efficacy.
Abstract
Description
FIELD OF THE INVENTIONThe present invention relates to a stable pharmaceutical composition ofpoorly soluble anti-fungal drug substances suitable for administration for theprophylaxis and treatment of fungal infections. The present invention particularlyrelates to a stable pharmaceutical composition of poorly soluble anti-fungal drugsubstance for desirable pharmacokinetic and better patient compliance.BACKGROUND OF THE INVENTIONOral intake has been the most prominent route of drug delivery by bothpatients and drug manufacturers for the treatment of most pathological states. Thelow aqueous soluble pharmaceutical drug substance is challenging to formulatebecause of less dissolution property which ultimately leads to less bioavailability.Various strategies have been widely investigated to enhance the bioavailability ofpoorly absorbed drugs to increase their clinical efficacy when administered orally.It is estimated that between 40% to 70% of all new chemical entities identified indrug discovery programs are insufficiently soluble in aqueous media.Posaconazole (PCZ) is a weakly basic small molecule as lipophilic drugsubstance with high permeability (>10-5cm / s) and low aqueous solubility (<1μg / ml), and with a pKa of 3.6 for the piperazine nitrogen and 4.6 for the triazolenitrogen. Due to its weak basicity, low solubility, and high permeability properties,posaconazole is considered a Biopharmaceutics Classification System (BCS) class2 drug substance. Because of these properties, when dissolved posaconazole entersthe intestinal tract environment, the dissolved posaconazole in the gastric stomachcrystallizes out which leads to low absorption and reduced bioavailability.The chemical name of posaconazole is 4-[4-[4-[4-[[(3R,5R) - 5 - (2,4-difluorophenyl) tetrahydro - 5 - (1H - 1,2,4 - triazol - 1 -ylmethyl) - 3 - furanyl]methoxy] phenyl]-1-piperazinyl] phenyl] - 2 - [(1S,2S)-1-ethyl-2-hydroxypropyl]- 2,4 - dihydro-3H-1,2,4-triazol-3-one and has the following structure as mentionedin below figure:The drug substance, posaconazole, is an antifungal agent that belongs to thetriazole group. It works by preventing the formation of ergosterol, which is animportant part of fungal cell walls. Posaconazole inhibits the enzyme lanosterol14α-demethylase (CYP51), which catalyzes an essential step in ergosterolbiosynthesis, and without ergosterol, the fungus dies or is prevented fromspreading.Posaconazole is indicated for use in the treatment of invasive aspergillosis,fusariosis, chromoblastomycosis, mycetoma, coccidioidomycosis. Posaconazole isalso indicated in adults for prophylaxis of invasive fungal infections.Saksena et al., United States Patent No. 5,661,151 discloses the triazoleantifungal agent posaconazole and its potent antifungal activity against a broadrange of fungi such as aspergillus, candida, cryptococcus, fusarium, and otheropportunistic fungi.Sangekar et al., United States Patent No. 5,834,472 describe apharmaceutical composition of posaconazole, a non-ionic surfactant that is a blockcopolymer of ethylene oxide, propylene oxide and a diluent.Sharpe et al., WO2002080678 describes pharmaceutical compositions ofposaconazole together with at least one thickening agent, a non-ionic surfactant,and a pharmaceutically acceptable liquid carrier, and methods of using thesuspensions to treat or prevent fungal infections.Posaconazole is commercialized under the brand name Noxafil with oneof the dosage form as an oral capsule-shaped tablet with dimensions, approximately18 mm length, 7 mm width and 6.5 mm thickness. The recommended loading doseis 600 mg posaconazole (six 100 mg tablets) as an oral twice daily dose with orwithout food and the maintenance dose is 300 mg posaconazole (three 100 mgtablets) as an oral single daily dose with or without food. Therefore, a patient needsto take six tablets to fulfill the loading dose and three tablets to fulfill themaintenance dose. The tablet should be swallowed whole with water. This pillburden during therapy results in a patient in compliance. Thus, as mentioned herecommercially available product Noxafil is having issues of big unit tablet size,problems of difficulty in swallowing, which may result in a situation like dysphagia.This situation ultimately results in very poor patient compliance.There is always difficulty in making soluble dosage forms with acceptablesize for oral administration due to poor solubility of the drug in lipophilic oils orpolymeric carriers. Posaconazole drug substance is also having a similar kind ofchemical property which forms difficulties in developing proper dosage forms andultimately leads to poor patient compliance.However, none of the above-mentioned prior art includes the aspects of dosereduction and reduction of pill burden in comparison to the currently availableformulation of posaconazole using lipidic drug delivery system basedpharmaceutically stable dosage form.Therefore, there is an unmet need to provide pharmaceutical dosage form ofpoorly soluble posaconazole with smaller size unit dose composition which can beeasily swallowed by patients and / or having a smaller number of units per dailyrecommended dose which ultimately leads to better patient compliance. At the sametime, there is a need for a single unit dosage form of poorly soluble posaconazoledrug substance which can incorporate a higher amount of drug with improveddissolution and bioavailability. Additionally, there is a need to reduce the necessarydaily dose of poorly soluble posaconazole. The present invention aimed to addressthe above-mentioned problems of the posaconazole drug substance by improvingthe dissolution and bioavailability of posaconazole which subsequently improvespatient compliance and reduces the overall cost of therapy.SUMMARY OF THE INVENTIONThe present invention provides a stable pharmaceutical compositioncontaining poorly soluble tri-azole anti-fungal (TAAF) drug substance. The presentinvention relates to a stable pharmaceutical dosage form of poorly soluble TAAFdrug substance with improved dissolution, bioavailability, and better patientcompliance.One of the aspect of the present invention includes stable lipidic drugdelivery system pharmaceutical composition of poorly soluble TAAF drugsubstance and one or more pharmaceutically acceptable excipients thereof. Inanother aspect of the present invention, the stable lipidic drug delivery systempharmaceutical composition includes nanostructured lipid carriers (NLCs), solidlipid nanoparticles (SLNs), liposomes or niosomes.In one another aspect, the present invention provides a nanostructured lipidcarriers based pharmaceutically stable composition containing a poorly solubleTAAF drug substance and one or more pharmaceutically acceptable excipientsthereof. In one another aspect, the present invention provides a process for thepreparation of a nanostructured lipid carriers based pharmaceutical compositioncontaining a poorly soluble TAAF drug substance and one or morepharmaceutically acceptable excipients thereof including but not limited to solidlipid, liquid lipid, surfactant, or combinations thereof.In one another aspect, prepared nanostructured lipid carrier pharmaceuticalcomposition of the present invention may also be used to prepare pharmaceuticaldosage forms like minicapsule, capsule, tablet, minitablet, suspension, solution,chewable tablet, orally disintegrating tablet, dispersible tablet, granule, sprinkle,pellet, bead, powder, dry powder for suspension or sachet dosage form, etc.BRIEF DESCRIPTION OF DRAWINGSFigure 1: Cumulative percentage drug release of PCZ-NLCs at 360 minutes on t0,t0+2M, t0+6M at 25°C±2°C / 65±5%RH as per ICH guidelineFigure 2: Cumulative percentage drug release of PCZ-NLCs at t0, t0+1M, t0+3M at40°C±2°C / 75±5%RH as per ICH guidelineFigure 3: TEM (Transmission electron microscopy) Analysis of PCZ-NLCsoptimized formulationFigure 4: In-vivo plasma drug concentration-time curveDETAILED DESCRIPTIONThe stable pharmaceutical compositions of a poorly soluble anti-fungal drugsubstance have been developed in response to the present state of the art, and inparticular, in response to the problems and unmet needs in the art that have not beenfully solved.As used herein, unless otherwise indicated, the term "poorly soluble" refersto slightly soluble or very slightly soluble drug substance and it requires from about100 or more parts of solvent for one part of solute and wherein the poorly solublemeans the solubilization of drug substance becomes the rate-limiting step forachieving desired bioavailability of such drug substance. It also refers to a drugsubstance that has a solubility of less than 10 mg / ml, and preferably less than about5 mg / ml, and more preferably less than about 1.0 mg / ml in aqueous media.As used herein, unless otherwise indicated, the term "tri-azole anti-fungal"(TAAF) drug substance refers to posaconazole and also other compounds withsimilar anti-fungal properties and having similar physicochemical properties and itmay include pharmaceutically acceptable derivative, pro-drug, salt, ester,polymorph, or isomer of that recited TAAF drug substance.As used herein, unless otherwise indicated, the term "active ingredient"refers to one or more TAAF drug substance or a combination thereof and it mayinclude pharmaceutically acceptable derivatives, pro-drug, salt, ester, polymorph,or isomer of that recited TAAF drug substance.As used herein, unless otherwise indicated, the terms "about" and"approximately" should be understood to mean within an acceptable error range forthe particular value as determined by one of ordinary skill in the art, which willdepend in part on how the value is measured or determined, i.e., the limitations ofthe measurement system. For example, "about" can mean a range of up to 20%,preferably up to 10%, more preferably up to 5%, and more preferably still up to 1%of a given value.As used herein, unless otherwise indicated, the term "stable" refers to acomposition that retains its properties without loss of potency of the active andmaintains its physical characteristics over time with minimal degradation.As used herein, unless otherwise indicated, the terms "microglobules","microparticles", "microparticulate" or "microsized particles", which are usedinterchangeably herein, refer to globules which exhibit a mean globule size that issmaller than about 1000 nm in every dimension. Preferably, "microglobules","microparticles", "microparticulate" or "microsized particles" exhibit a meanglobule size smaller than about 500 nm in every dimension. More preferably, itrefers to globules which exhibit a mean globule size smaller than about 250 nm inevery dimension.As used herein, unless otherwise indicated, the terms "nanoglobules","nanoparticles", "nanoparticulate" or "nanosized particles", which are usedinterchangeably herein, refer to globules which exhibit a mean globule size that issmaller than about 1000 nm in every dimension. Preferably, "nanoglobules","nanoparticles", "nanoparticulate" or "nanosized particles" exhibit a mean globulesize smaller than about 500 nm in every dimension. More preferably, it refers toglobules which exhibit a mean globule size smaller than about 200 nm in everydimension.As used herein, unless otherwise indicated, the term "microemulsion" canbe defined as a colloidal dispersion of micro-sized drug globules.As used herein, unless otherwise indicated, the term "nanostrucutred lipidcarriers (NLCs)" refers to pharmaceutical composition composed of solid lipid,liquid lipid and surfactant.As used herein, unless otherwise indicated, the term "solid lipidnanoparticles (SLNs)" refers topharmaceutical composition composed of solid lipidand surfactant.As used herein, unless otherwise indicated, the term "nanoemulsion" can bedefined as a colloidal dispersion of nano-sized drug globules.As used herein, unless otherwise indicated, the term "surfactant" usedherein is, as generally understood by persons skilled in the art, a substance that canlower the surface tension or interfacial tension between two liquids or between aliquid and a solid. Preferably, the term "surfactant" used herein means a substancecapable of acting as a wetting agent, as an emulsifier, as detergent, and as adispersant. The general function of a substance being a surfactant may be typicallyknown in advance by a person skilled in the art.As used herein, unless otherwise indicated, the term "co-surfactant" usedherein is, as generally understood by persons skilled in the art, a substance that cancan enhance the emulsification or stabilizing power or effect of the surfactant.As used herein, unless otherwise indicated, the term "pharmaceuticallyacceptable" as used herein means a pharmaceutically acceptable non-toxic material,composition or carrier, such as an encapsulating liquid or solid filler, diluent,excipient, solvent, dispersant, adjuvant or other material, which is mixed with theactive ingredient in order to permit the formation of a pharmaceutical composition,involved in making or transporting the subject organ or body portion to anotherorgan or body portion.As used herein, unless otherwise indicated, the term "bioavailability"indicates the extent to which a drug or another substance is utilized by a target tissueafter administration.As used herein, unless otherwise indicated, the term "AUC0-∞," means thearea under a plasma drug concentration-time curve from the time point of 0 toinfinity after drug administration, and the term "AUC0-t" means the area under aplasma drug concentration-time curve from the time point of 0 to t after drugadministration.As used herein, unless otherwise indicated, the term "peak plasma drugconcentration (Cmax)" means the maximum plasma drug concentration attained afterdrug administration.As used herein, unless otherwise indicated, the term "peak time of plasmadrug concentration (Tmax)" means the time when peak plasma drug concentration(Cmax) is attained after drug administration.As used herein, unless otherwise indicated, the term "shelf life" refers to thestorage stability time period during which pharmaceutical composition and / oractive ingredient is expected to remain stable within defined specification as perICH guidelines and / or pharmacopeia guidelines.As used herein, unless otherwise indicated, the term "ICH guidelines"means composition remains stable for a longer period at 5°C±3°C, 25°C ± 2°C / 60%RH ± 5% RH, 30°C ± 2°C / 65% RH ± 5% RH or 40°C ± 2°C / 75% RH ± 5% RHconditions for at least 6 months.The present invention relates to stable pharmaceutical dosage form of apoorly soluble TAAF drug substance and one or more pharmaceutically acceptableexcipients thereof with improved dissolution and bioavailability with better patientcompliance. The present invention also relates to a pharmaceutical composition ofpoorly soluble TAAF drug substance and one or more pharmaceutically acceptableexcipients thereof which can be easily swallowed by patients and / or having asmaller number of units per daily recommended dose which ultimately leads tobetter patient compliance. Further, the present invention also relates to stablepharmaceutical composition of poorly soluble TAAF drug substance and one ormore pharmaceutically acceptable excipients thereof in form of single unit dosageform which can incorporate higher amount of drug with improved dissolution andbioavailability. Additionally, it may comprise stable pharmaceutical compositionwith a reduced daily dose of poorly soluble TAAF drug substance compare tocurrent recommended doses. According to the present invention, in order to achieveabove-mentioned characteristics for poorly soluble TAAF drug substance,nanostructured lipid carrier based pharmaceutically stable compositions aredeveloped.In another aspect of the present invention, the stable pharmaceuticalcomposition comprises lipidic drug delivery basedpharmaceutically stablecomposition of poorly soluble TAAF drug substance and one or morepharmaceutically acceptable excipients thereof. In one aspect of the presentinvention, the stable pharmaceutical composition comprises poorly soluble TAAFdrug substance incorporated in NLCs or SLNs. In one another aspect, the presentinvention provides a nanostructured lipid carriers based pharmaceuticalcomposition containing a poorly soluble TAAF drug substance posaconazole andone or more pharmaceutically acceptable excipients including but not limited tosolid lipid, liquid lipid, surfactant and combinations thereof.Moreover, according to one of the embodiment, the process for preparing alipidic drug delivery based pharmaceutical composition of the poorly soluble TAAFdrug substance and one or more pharmaceutically acceptable excipients thereof canbe one or more techniques known for various methods by the person skilled in theart at the time of the present invention like but not limited to high pressurehomogenization (HPH), microemulsion, emulsification-solvent evaporationmethod, emulsification-solvent diffusion method, solvent injection (or solventdisplacement) method, phase inversion, multiple emulsion, ultrasonication andmembrane contractor technique. According to one of the embodiments of thepresent invention, the techniques for preparing NLCs or SLNs based formulationinclude but not limited to high pressure homogenization method. In one anotherembodiment of the present invention, the high pressure homogenization techniquefor preparing NLCs or SLNs based formulation may include but not limited to hothigh pressure homogenization, cold high pressure homogenization or other similarmethods.In one of the embodiment, the process for the preparation of lipidic carrierbased pharmaceutical composition may include: (a) mixing of the solid lipid withliquid lipid by melting both the components at above melting temperature followedby addition of drug to form homogenous lipid phase mixture ; (b) preparation ofhot aqueous surfactant phase by heating at the same temperature as of lipid phase ;(c) addition of melted lipid phase dropwise hot aquous surfactant phase withcontinuous stirring to form primary emulsion.; (d) homogenization of the entire preemulsion mixture by applying high shear by homogenizer.In one another aspect of the present invention, the lipidic carrier basedpharmaceutically stable composition of poorly soluble posaconazole drugsubstance may have average sizes less than about 1000 nm, or less than about 800nm, or less than about 500 nm. In one of the embodiments, the preferable particlesize of particle size of poorly soluble TAAF drug substance posaconazole is lessthan about 500 nm. In one of the embodiments, more preferable particle size ofparticle size of poorly soluble TAAF drug substance posaconazole is less thanabout 250 nm.Non-limiting examples of pharmaceutically acceptable excipients are,Lipids:The lipids (solid / liquid) used for the preparations of stablepharmaceutical composition of poorly soluble TAAF drug substance posaconazoleinclude but not limited to medium-chain mono and diglycerides, medium-chaintriglyceride, long-chain monoglycerides, propylene fatty acid esters, fatty acidesters or combinations thereof. The long-chain monoglycerides include but notlimited to glyceryl monooleate (e.g. Peceol, Capmul-GMO and alike orcombinations thereof). The propylene fatty acid esters include but not limited topropylene glycol monocaprylate, propylene glycol monolaurate / dilaurate,propylene glycol dicaprylate / caprate (e.g. Capryol 90, Capmul PG-8, Sefsol,Capmul PG-12, Lauroglycol FCC, Miglyol 840, Captex 200 and alike orcombinations thereof), propylene glycol mono- and di- esters of lauric (C12) acid(e.g. propylene glycol monolaurate (Lauroglycol 90) and alike thereof ), propyleneglycol mono- and di- esters of lauric (C12) acid (Propylene glycol monocaprylate(Capryol PGMC) and alike thereof). The medium-chain mono and diglyceridesinclude but not limited to Mono- and di-glycerides of capric / caprylic acids (CapmulMCM, Imwitor 742, Akoline MCM and alike and combinations thereof). Themono-, di- and triglycerides and mainly PEG-8 mono- and diesters of caprylic (C8)and capric (C10) acids includes but not limited to caprylocaproyl Polyoxyl-8glycerides (Labrasol ALF). The medium-chain triglyceride includes but not limitedto Triglycerides of capric / caprylic acids (e.g. Miglyol 810, Miglyol 812, Miglyol812 N, Labrafac lipophile WL 1349, Labrafac CC, Crodamol GTCC, Captex 300,355 and alike or combinations thereof), Triacetin (e.g. Captex 500 and alike orcombinations thereof). The monoesters, diesters, and triesters of glycerol andmonoesters and diesters of polyethylene glycols includes but not limited to PEG-8caprylic / capric glycerides (Acconon MC-82) or alike thereof. The fatty acid estersinclude but not limited to ethyl oleate (e.g. Crodamol EO and alike thereof), oleicacid, isopropyl myristate and alike to combinations thereof. The natural oils includebut not limited to Castor Oil, Olive Oil, Soyabean Oil, Corn oil and alikeorcombinations thereof. The preferebale solid lipids used for the preparations ofstable pharmaceutical composition of poorly soluble TAAF drug substanceposaconazole include but not limited to Glyceryl tristearate (Triacylglycerols) (e.g.Tristearin and alike or combinations thereof), Glyceryl Monostearate(Acylglycerols) (e.g. Imwitor 491 and alike or combinations thereof), PropyleneGlycol (PG) Fatty Acid Ester (e.g. Precirol ATO 5 and alike or combinationsthereof), Glyceryl dibehenate (Acylglycerols) (e.g. Compritol 888 ATO and alikeor combinations thereof), Fatty acids(e.g. stearic acid, Gelucire 43 / 01, palmitic acidand alike or combinations thereof), medium chain triglycerides (e.g. Gelucire 39 / 1and alike or combinations thereof), Cetyl palmitate (Waxes) (e.g. Crodamol CP andalike or combinations thereof) and alike or combinations thereof. The preferebaleliquid lipids used for the preparations of stable pharmaceutical composition ofpoorly soluble TAAF drug substance posaconazole include but not limited toOleoyl polyoxyl-6 glycerides (e.g. Labrafil M 1944 CS and alike or combinationsthereof), Diethylene glycol monoethyl ether (e.g. Transcutol HP and alike orcombinations thereof), Propylene Glycol Dicaprylate (Medium-ChainTriglycerides) (e.g. Miglyol 812 and alike or combinations thereof), Isopropylmyristate, Caprylocaproyl Polyoxyl-8 glycerides (e.g. Labrasol ALF and alike orcombinations thereof), Long chain triglyceride (e.g. castor oil, olive oil, corn oiland alike or combinations thereof), Propylene glycol and alike or combinationsthereof.Surfactants:The surfactants or co-surfactants used for the preparations of stablepharmaceutical composition of poorly soluble TAAF drug substance posaconazoleinclude but not limited to anionic surfactants, cationic surfactants, non-ionicsurfactants, zwitterionic surfactants or combinations thereof. The anionic surfactantincludes but not limited to sodium lauryl sulfate, ammonium lauryl sulfate, sodiumlauryl ether sulfate, sodium myreth sulfate, sodium stearate, dioctyl sodiumsulfosuccinate, perfluorooctanesulfonate, linear alkylbenzene sulfonates,perfluorobutanesulfonate, alkyl-aryl ether phosphates, alkyl ether phosphates,sodium lauroyl sarcosinate, perfluorononanoate, perfluorooctanoate and alike orcombinations thereof. The cationic surfactant includes but not limited to quaternaryammonium compound (e.g. benzalkonium chloride, cetylpyridinium chloride,benzethonium chloride and alike and combinations thereof), alkyl ammonium salt(e.g. alkyl trimethylammonium salts, cetyltrimethylammonium bromide,cetyltrimethylammonium chloride, dimethyldioctadecylammonium chloride,dioctadecyldimethylammonium bromide and alike or combinations thereof),octenidine dihydrochloride and alike or combinations thereof. The non-ionicsurfactant includes but not limited to mono-, di- and triglycerides and PEG-6 (MW300) mono- and diesters of linoleic (C18:2) acid (e.g. linoleoyl polyoxyl-6glycerides (Labrafil M 2125 CS) or alike thereof), polyoxyethylene alkyl ethers(e.g. polyoxyethylene glycol octylphenol ethers, polyoxyethylene glycolalkylphenol ethers and alike thereof), polyoxyethylene sorbitan fatty acid esters,polyoxyethylene stearates, sorbitan fatty acid esters, polyoxyethylene castor oilderivatives (e.g. polyoxyl 60 hydrogenated castor oil (Acrysol K-160), Polyoxyl 40hydrogenated castor oil (Kolliphor RH 40) or alike thereof), block copolymers ofpolyethylene glycol, polypropylene glycol, alkyl poly(ethylene oxide), copolymersof poly(ethylene oxide) and poly(propylene oxide), alkyl polyglucosides (e.g. octylglucoside, decyl maltoside and alike or combinations thereof), fatty alcohols (e.g.cetyl alcohol, oleyl alcohol and alike or combinations thereof), fatty acid amides(e.g. cocamide monoethanolamine, cocamide diethanolamine and alike orcombinations thereof), dodecyl dimethylamine oxide, vitamin E-TPGS,caprylocaproyl macrogol glycerides, alkyl aryl polyether alcohol (e.g. tyloxapol),polyoxyethylenesorbitan monooleate (e.g. Tween 80), polyoxyethylenesorbitanmonolaurate (e.g. Tween 20) and alike or combinations thereof. The zwitterionicsurfactant includes but not limited to (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate), cocamidopropyl hydroxysultaine, cocamidopropyl betaine,phospholipids phosphatidylserine, phosphatidylethanolamine,phosphatidylcholine, phosphatidyl choline-enriched lecithin, sphingomyelins,lecithin and alike or combinations thereof. The preferebale surfactants or cosurfactant used for the preparations of stable pharmaceutical composition of poorlysoluble TAAF drug substance posaconazole include but not limited to Poly(ethylene glycol)-block-poly (propylene glycol)-block-poly (ethylene glycol) (e.g.Pluronic F 127 (poloxamer 407) and alike or combinations thereof),Polyoxyethylene-polyoxypropylene block copolymer (e.g. Pluronic F 68(poloxamer 188) and alike or combinations thereof), Sorbitan monooleate (e.g.Tween 80, Span 80 and alike or combinations thereof), soy lecithin and alike orcombinations thereof.In one of the embodiment of the present invention, the poorly soluble TAAFdrug substance may administered as a unit stable nanostructured lipid carrier basedpharmaceutical composition, for example, containing 0.05 to 1000 mg by weight,preferably 0.5 to 1000 mg by weight, more preferably 5 to 500 mg by weight ofposaconazole to toal pharmaceutical composition. In some embodiments of thepresent invention, a stable pharmaceutical composition may comprise, for example,at least about 0.1% by weight or at least about 5% by weight or at least about 20%by weight or at least about 50% by weight or at least about 75% by weight ofposaconazole.In accordance with one of the embodiments, the present invention providesa pharmaceutical composition in the form of a nanostructured lipid carriers (NLCs)based composition of a liquid lipid, solid lipid, surfactant or mixtures thereof andposaconazole, wherein the composition forms a dispersion, in vitro.In accordance with one another embodiment, the present invention furtherprovides a pharmaceutical composition of a poorly soluble TAAF drug substanceposaconazole in the form of NLCs which comprises a Glyceryl tristearate(Triacylglycerols) (Tristearin), Oleoyl polyoxyl-6 glycerides (Labrafil M 1944 CS)or Polyoxyethylene-polyoxypropylene block copolymer (Pluronic F 68 (poloxamer188)) and one or more combinations thereof, wherein the composition forms adispersion or solution in vitro and provides acceptable absorption in vivo.In accordance with one another embodiment, the present invention furtherprovides a pharmaceutical composition of a poorly soluble TAAF drug substanceposaconazole in the form of a NLCs which comprises a Tristearin, Labrafil M 1944CS or Pluronic F 68 and one or more combinations thereof, wherein thecomposition forms a dispersion or solution in vitro and provides acceptableabsorption in vivo.According to another embodiment of this present invention, the doseadministered must be carefully adjusted according to age, weight and condition ofthe patient, as well as the route of administration, dosage form and regimen and thedesired result. According to one another embodiment of this present invention,dosage forms can be administered to the patient on a regimen of, for example, one,two, three, four, five, six, or other doses per day.The inventors of the present invention have found that modification insolubility of posaconazole or a pharmaceutically acceptable salt thereof,specifically by preparation of NLCs, offers advantages over currently availableformulation owing to enhanced solubility which leads to improved bioavailabilityof posaconazole which in turn reduces the pill burden and improves patientcompliance. Thus, improved solubility results in improved dissolution in-vivo andhence improved bioavailability of finished drug product. Further, the reduced pillburden due to reduced dose may also lead to a reduction in side effects ofposaconazole observed with the usual dosing regimen. In accordance with thepresent invention, it has been found that drugs previously considered to presentpoor bioavailability may be presented in pharmaceutical dosage forms with higherbioavailability.The solid lipid used in the pharmaceutical composition of the presentinvention may present in an amount from about 10% to about 99% by weight of thepharmaceutical composition, preferably from about 25% to about 95% by weightof the pharmaceutical composition and is more preferably employed in an amountin a range of from about 45% to about 95% by weight of the pharmaceuticalcomposition.The liquid lipid used in the pharmaceutical composition of the presentinvention may present in an amount from about 10% to about 90% by weight of thepharmaceutical composition, preferably from about 10% to about 70% by weightof the pharmaceutical composition and is more preferably employed in an amountin a range of from about 10% to about 45% by weight of the pharmaceuticalcomposition.The surfactant used in the pharmaceutical composition of the presentinvention may present in an amount up to about 50% by weight of thepharmaceutical composition, preferably up to about 30% by weight of thepharmaceutical composition and is more preferably employed in an amount up toabout 10% by weight of the pharmaceutical composition.According to one of the embodiment of the present invention, ananostructured lipid carrier based pharmaceutical composition comprising fromabout 10% to about 40% by weight of poorly soluble TAAF drug substance or apharmaceutically acceptable salt thereof, from about 20% to about 55% by weightof solid lipid, from about 10% to about 40% by weight of liquid lipid, and up toabout 10% by weight of surfactant.According to one of the embodiment of the present invention, ananostructured lipid carrier based pharmaceutical composition comprising fromabout 10% to about 40% by weight of posaconazole or a pharmaceuticallyacceptable salt thereof, from about 20% to about 55% by weight of Glyceryltristearate (Triacylglycerols) (Tristearin), from about 10% to about 40% by weightof Oleoyl polyoxyl-6 glycerides (Labrafil M 1944 CS), and up to about 10% byweight of Polyoxyethylene-polyoxypropylene block copolymer (Pluronic F 68(poloxamer 188)).According to one of the embodiment of the present invention, a lipidiccarrier based nanoparticulate pharmaceutical composition comprising about 20%by weight of posaconazole or a pharmaceutically acceptable salt thereof, from about49% by weight of Glyceryl tristearate (Triacylglycerols) (Tristearin), about 26%by weight of Oleoyl polyoxyl-6 glycerides (Labrafil M 1944 CS), about 4% byweight of Polyoxyethylene-polyoxypropylene block copolymer (Pluronic F 68(poloxamer 188)) and optionally, about 1% by weight of soy lecithin.According to one of the embodiment of the present invention, ananostructured lipid carrier based pharmaceutical composition comprising about20% by weight of posaconazole or a pharmaceutically acceptable salt thereof, fromabout 49% by weight of Glyceryl tristearate (Triacylglycerols) (Tristearin), about26% by weight of Oleoyl polyoxyl-6 glycerides (Labrafil M 1944 CS), about 4%by weight of Polyoxyethylene-polyoxypropylene block copolymer (Pluronic F 68(poloxamer 188)) and optionally, about 1% by weight of soy lecithin.The present invention also provides a process for preparing apharmaceutical composition of a practically insoluble TAAF drug substance, theprocess including high shear homogenization of mixture of liquid lipid, solid lipidand surfactant with drug substance.According to one of the embodiment of the present invention, a process forpreparing nanoparticulate lipic carrier based pharmaceutical composition of thepoorly soluble TAAF drug substance and one or more pharmaceutically acceptableexcipients thereof, wherein the process includes the steps of: (a) mixing of the solidlipid with liquid lipid by melting both the components at above melting temperaturefollowed by addition of drug to form homogenous lipid phase mixture ; (b)preparation of hot aqueous surfactant phase by heating at the same temperature asof lipid phase ; (c) addition of melted lipid phase dropwise hot aquous surfactantphase with continuous stirring to form primary emulsion.; (d) homogenization ofthe entire pre-emulsion mixture by applying high shear by homogenizer.According to one of the embodiment of the present invention, a process forpreparing nanoparticulate lipic carrier based pharmaceutical composition of thepoorly soluble TAAF drug substance and one or more pharmaceutically acceptableexcipients thereof, wherein the process includes the steps of: (a) mixing of theTristearin with Labrafil M 1944 CS by melting both the components at abovemelting temperature followed by addition of accurately weighed posaconazole toform homogenous lipid phase mixture ; (b) preparation of hot aqueous surfactantphase by heating Pluronic F 68 (poloxamer 188) at the same temperature as of lipidphase mixture; (c) addition of melted lipid phase dropwise hot aquous surfactantphase with continuous stirring to form primary emulsion at about 10,000 rpm; (d)homogenization of the entire pre-emulsion mixture by applying high shear byhomogenizer for about 5 to about 12 cycles.According to one of the embodiment of the present invention, a process forpreparing nanoparticulate lipic carrier based pharmaceutical composition of thepoorly soluble TAAF drug substance and one or more pharmaceutically acceptableexcipients thereof, wherein the process includes the steps of: (a) mixing of about20% by weight to about 55% by weight of Tristearin with about 10% by weight toabout 40% by weight of Labrafil M 1944 CS by melting both the components atabove melting temperature followed by addition of about 10% by weight to about40% by weight of posaconazole to form homogenous lipid phase mixture; (b)preparation of hot aqueous surfactant phase by heating upto about 10% by weightof Pluronic F 68 (poloxamer 188) at the same temperature as of lipid phase mixture;(c) addition of melted lipid phase dropwise hot aquous surfactant phase withcontinuous stirring to form primary emulsion at about 10,000 rpm; (d)homogenization of the entire pre-emulsion mixture by applying high shear byhomogenizer for about 5 to about 12 cycles.According to one of the embodiment of the present invention, a process forpreparing nanoparticulate lipic carrier based pharmaceutical composition of thepoorly soluble TAAF drug substance and one or more pharmaceutically acceptableexcipients thereof, wherein the process includes the steps of: (a) mixing of about49% by weight of Tristearin with about 26% by weight of Labrafil M 1944 CS bymelting both the components at about 5°C above melting temperature of lipidsfollowed by addition of about 20% by weight of posaconazole to form homogenouslipid phase mixture; (b) preparation of hot aqueous surfactant phase by heatingabout 4% by weight of Pluronic F 68 (poloxamer 188) at the same temperature asof lipid phase mixture; (c) addition of melted lipid phase dropwise hot aquoussurfactant phase with continuous stirring to form primary emulsion at about 10,000rpm; (d) homogenization of the entire pre-emulsion mixture by applying high shearby homogenizer for about 5 to about 12 cycles.In a further embodiment, the present invention relates to a method oftreating fungal infections by administering a stable NLCs pharmaceuticalcomposition of poorly soluble TAAF drug substance, wherein the formed NLCscomposition is further formulated in form of a soft capsule, hard capsule, powderor compressed into a tablet or alike similar dosage form.According to another embodiment of this present invention, a stablepharmaceutical composition of poorly soluble TAAF drug substance and one ormore pharmaceutically acceptable excipients thereof can be provided in the formof minicapsule, capsule, tablet, minitablet, suspension, solution, chewable tablet,orally disintegrating tablet, dispersible tablet, granule, sprinkle, pellet, bead,powder, dry powder for suspension or sachet dosage form. These forms are wellknown in the art and are packaged appropriately.According to another embodiment of this present invention, a NLCs basedcomposition can be coated with one or more enteric coatings, seal coatings, filmcoatings, barrier coatings, or fast disintegrating coatings. Further, the dosage formcan be designed for immediate release, controlled release or extended-release of apoorly soluble TAAF drug substance.According to another embodiment, a NLCs based composition of poorlysoluble TAAF drug substance may be further formulated according to acceptedpharmaceutical practice with one or more pharmaceutically acceptable excipients,wherein one or more pharmaceutically acceptable excipients may include diluents,binders, disintegrants, glidants, lubricants, preservative, stabilizer, flavoring agent,sweetening agent or mixtures thereof.Non-limiting examples of diluents that may be suitable for use in the presentinvention for further formulating poorly soluble TAAF drug substance includeinorganic phosphates like dibasic calcium phosphate, sugars or sugar analogues andderivatives thereof (e.g. lactose, such as lactose monohydrate or water-free lactose,dextrose, sorbitol, mannitol, saccharose, maltodextrin, isomalt, etc.), celluloses(e.g. microcrystalline cellulose, etc.) or alike thereof. The diluents may present inan amount of about 1% to about 90% by weight of the composition, preferably ofabout 10% to about 80% by weight of the composition, more preferably of about40% to about 70% by weight of the composition. Non-limiting examples of bindersthat may be suitable for use in the present invention for further formulating poorlysoluble TAAF drug substance include polyvinylpyrrolidone, starch, cellulosederivatives like hydroxypropyl methyl cellulose, sucrose, lactose, xylitol, sorbitol,maltitol, water, alcohol or polyethelyne glycol or a like thereof. According to thepresent invention, preferable binder is lactose, polyvinylpyrrolidone orpolyethelyne glycol. The binders may present in an amount of about 1% to about90% by weight of composition, preferably of about 10% to about 70% by weightof composition. Non-limiting examples of disintegrants that may be suitable for usein the present invention for further formulating poorly soluble TAAF drugsubstance include sodium starch glycolate, alginates, pregelatinized starch,croscarmellose and cross-linked polyvinylpyrrolidone and alike or combinationsthereof. The disintegrants may present in an amount of about 1% to about 10% byweight of composition, preferably of about 4% to about 8% by weight ofcomposition.In accordance with one of the embodiments, the present invention providesa pharmaceutical composition can also have altered absorption behavior ofposaconazole in vitro and vivo, increasing Cmax and AUC without prolonging Tmax.In accordance with one another embodiments, the reduced dose pharmaceuticalcomposition of the present invention shows mean Cmax from about 200 ng / ml toabout 4000 ng / ml.Additionally, in another embodiment of present invention, thepharmaceutical composition of the present invention potentially reduces the sideeffects due to reduced dose of posaconazole used in the prophylaxis or treatment ofinvasive fungal infections caused by, but not limited to aspergillus, zygomycetes,candida, cryptococcus and fusarium species.The following examples further describe certain specific aspects andembodiments of the disclosure. However, one skilled in the art will appreciate thatthe specific methods and results discussed are provided only for purposes ofillustration and should not be construed as limiting the scope of the disclosure inany manner, as many variations thereof are possible without departing from thespirit and scope of the invention. Having thus described in detail preferredembodiments of the present invention, it is to be understood that the inventiondefined by the above paragraphs is not to be limited to particular details set forth inthe above description as many apparent variations thereof are possible withoutdeparting from the spirit or scope of the present invention.Example 1: Preparation of nanostructured lipid carrier based pharmaceuticalcomposition of posaconazoleTable 1 Percentage range of formulation ingredientsSr. No. Ingredients Amount (%w / w)1. Posaconazole 10-402. Glyceryl tristearate (Triacylglycerols) 20-553. Oleoyl polyoxyl-6 glycerides 10-404. Polyoxyethylene-polyoxypropylene block copolymer 1-10Procedure:a) Mixing of about 20% by weight to about 55% by weight of Glyceryl tristearate(Triacylglycerols) with about 10% by weight to about 40% by weight of Oleoylpolyoxyl-6 glycerides by melting both the components at above meltingtemperature followed by addition of about 10% by weight to about 40% byweight of posaconazole or pharmaceutically acceptable salts thereof to formhomogenous lipid phase mixture;b) preparation of hot aqueous surfactant phase by heating upto about 10% byweight of polyoxyethylene-polyoxypropylene block copolymer at the sametemperature as of lipid phase mixture;c) addition of melted lipid phase dropwise hot aquous surfactant phase withcontinuous stirring to form primary emulsion at about 10,000 rpm;homogenization of the entire pre-emulsion mixture by applying high shear byhomogenizer for about 5 to about 12 cycles.Example 2: Preparation of optimised nanostructured lipid carrier basedpharmaceutical composition of posaconazoleTable 2 Optimised formulation of NLC based composition of PCZSr. No. Ingredients Amount (% w / w)1. Posaconazole 202. Glyceryl tristearate (Triacylglycerols) (Tristearin) 493. Oleoyl polyoxyl-6 glycerides (Labrafil M 1944 CS) 264. Polyoxyethylene-polyoxypropylene block copolymer (Pluronic F 68 (poloxamer 188))5. Soy Lecithin 1Procedure:a) mixing of about 49% by weight of Tristearin with about 26% by weight ofLabrafil M 1944 CS by melting both the components at about 5°C abovemelting temperature of lipids followed by addition of about 20% by weight ofposaconazole to form homogenous lipid phase mixture;b) preparation of hot aqueous surfactant phase by heating about 4% by weight ofPluronic F 68 (poloxamer 188) at the same temperature as of lipid phase mixtureand optionally adding about 1% by weight of soy lecithin;c) addition of melted lipid phase dropwise hot aqueous surfactant phase withcontinuous stirring to form primary emulsion at about 10,000 rpm;d) homogenization of the entire pre-emulsion mixture by applying high shear byhomogenizer for about 5 to about 12 cycles.Example 3 Evaluation of optimised formulation for nanostructured lipid carrierbased composition of posaconazoleEvaluation of optimised formulation as mentioned in Example 2 has been carriedout and results are as mentioned in Table 3, Figure 1 and Figure 2.Table 3 Evaluation parameters for optimised formulation of NLCs basedcomposition of posaconazoleSr. No. Evaluation Parameter Results (Mean ± SD, n=3)1. Particle Size (nm) 158.6±1.262. In-vitro drug release at 360 min (cumulative percentage drug release) 92.01±2.113. Entrapment Efficiency (%) 91.11±0.394. Loading Capacity (%) 18.55±0.135. Polydispersity Index 0.260±0.0026. Zeta Potential (mV) -23mVExample 4 Evaluation of cumulative percentage drug releaseDissolution analysis of optimised formulation was been carried out usingUSP type II dissolution method with all parameters shown in Table 4 below. Toperform the release study of PCZ-NLCs, USP Type II paddle method wasemployed. Briefly, 750 ml of 0.1 N hydrochloric acid (for 120 Min) as acid stageand 250 ml of 0.20 M tribasic sodium phosphate; pH of 6.8 ± 0.05 as buffer stage(for 240 mins) with formulation equivalent to containing 100 mg of drug has beenused at a temperature of 37°±5°C. Aliquots of 5ml were withdrawn atpredetermined time intervals while maintaining the sink condition by replenishingwith the same volume of fresh media. The samples were analysed by the previouslyvalidated UV-VIS method (UV 1800, Shimadzu AS, Japan) for the estimation ofPCZ.Table 4 Dissolution parametersDissolution Medium Acid Stage 750 mL of 0.1 N hydrochloric acid (For 120 Min)Dissolution Medium Buffer Stage 250 mL of 0.20 M tribasic sodium phosphate; pH of 6.8 ± 0.05 (For 240 Mins)Temperature 37 °C ± 0.5 °CDosage 100 mgThe dissolution profile of posaconazole NLCs and marketed formulation ispresented in Figure 1. It clearly demonstrates the superior performance of thedeveloped PCZ-NLCs. The NLCs, presented PCZ in solubilized form in thedissolution media leading to enhanced and sustained dissolution rate.Example 5 Stability results of optimised formulation of Posaconazole NLCsAt the end of 2 month and 6 months stability at 25°C / 65%RH as per ICHguideline, it can be seen that the PCZ-NLCs retains its thermodynamic stabilityTable 5. Moreover, compared to marketed formulation optimised PCZ-NLCs hasshown better dissolution profile, which proves enhanced solubility profile of poorlysoluble PCZ compared to marketed formulation (Figure 1).Table 5 Stability Studies Results of posaconazole NLCs at t0+2M & t0+6MParameter t0 t0+2 Months t0+6 MonthsParticle Size (nm) 158.6±1.26 159.12±2.12 159.92±1.98In-vitro drug release at 360 min 92.01±2.11 91.201±1.09 94.901±2.367Entrapment Efficiency (%) 91.11±0.39 91.12±0.62 90.92±0.81Loading Capacity (%) 18.55±0.13 18.55±0.04 18.45±0.08Polydispersity Index 0.261±0.002 0.270±0.012 0.272±0.027Zeta Potential (mV) -23mV -22mV -23mVThe stability studies were carried out at accelerated conditions (AC) i.e., at40°C±2°C / 75 ± 5% RH, of optimized formulation and evaluated at end of 1 monthand 3 month stability. Possibility of the leaking of the drug is negligible based onthe in-vitro drug release data (Figure 2) and entrapment efficiency (Table 6).Table 6 Entrapment Efficiency (%) Results of PCZ-NLCs at end of t0+1M & t0+3M at ACStability Duration Entrapment Efficiency (%)t0+1 Months 90.08±0.56t0+3 Months 88.01±0.43Example 6 In-vivo pharmacokinetic study of Posaconazole NLCsA single dose bioavailability study was designed in healthy male wistar rats(weighing 170-200 g) under fasting conditions. The formulations were dispersedin pure water and then immediately administered to the rats by oral gavageaccording to the concentration of drug in the formulations for which all rats receivedoral doses of 10mg / kg. Three animals were used for each formulation. Bloodsamples (~0.5 mL) were drawn by retroorbital venous plexus puncture at 15 and30 min and 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours following oral administrationafter dose. The mean pharmacokinetic parameters such as total area under the curveAUC(0-72), half-life (t1 / 2), peak plasma concentration (Cmax), and time to reach themaximum plasma concentration (Tmax) were determined and as mentioned in Table7 and Figure 4.Table 7 Mean pharmacokinetic parametersFormulation Cmax (μg / mL) Tmax (Hour) AUC(0-72) (μg*hr / mL)Posaconazole NLCs 3.45±0.22 6.0 124.8Marketed Formulation 2.102±0.469 6.0 79.67
Claims
1. A stable nanostructured lipid carrier pharmaceutical composition comprising posaconazole or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients thereof.
2. The stable pharmaceutical composition according to claim 1, wherein the one or more pharmaceutically acceptable excipients comprising about 25% to about 95% by weight solid lipid, about 10% to about 70% by weight liquid lipid, about 2.5% to about 10% by weight surfactant or combinations thereof.
3. The stable pharmaceutical composition according to claim 2, wherein solid lipids selected from the group consisting of triacylglycerols, acylglycerols, glyceryl tristearate, glyceryl monostearate, propylene fatty acid esters, fatty acid esters, medium-chain mono- di- and triglycerides, long-chain monoglycerides and combinations thereof.
4. The stable pharmaceutical composition according to claim 3, wherein solid lipid is triacylglycerols or tristearin.
5. The stable pharmaceutical composition according to claim 2, wherein liquid lipids selected from the group consisting polyoxylglycerides, diethylene glycol monoethyl ether, propylene glycol, propylene glycol dicaprylate, isopropyl myristate, caprylocaproyl polyoxyl-8 glycerides, long chain triglyceride, medium-chain triglycerides, medium-chain mono- di- and triglycerides, long-chain monoglycerides and combinations thereof.
6. The stable pharmaceutical composition according to claim 5, wherein liquid lipid is oleoyl polyoxyl-6 glycerides or Labrafil M 1944 CS.
7. The stable pharmaceutical composition according to claim 2, wherein surfactant selected from the group consisting of anionic surfactants, cationic surfactants, non-ionic surfactants, zwitterionic surfactants and combinations thereof.
8. The stable pharmaceutical composition according to claim 7, wherein surfactant is polyoxyethylene-polyoxypropylene block copolymer or Pluronic F 68.
9. A stable nanostructured lipid carrier pharmaceutical composition comprising, from about 10% to about 40% by weight posaconazole or pharmaceutically acceptable salts thereof, about 20% to about 55% by weight tristrearin, about 10% to about 40% by weight Labrafil M 1944 CS and about 2.5% to about 10% by weight Pluronic F 68.
10. A stable nanostructured lipid carrier pharmaceutical composition prepared by a process comprising the steps of: (a) mixing of Tristearin with Labrafil M 1944 CS by melting both the components at above melting temperature of lipids followed by addition of about 0.1% to about 60% by weight posaconazole or pharmaceutically acceptable salts thereof to form homogenous lipid phase mixture; (b) preparation of hot aqueous surfactant phase by heating Pluronic F 68 at the same temperature as of lipid phase mixture and optionally adding about 1% by weight of soy lecithin; (c) addition of melted lipid phase dropwise hot aqueous surfactant phase with continuous stirring to form primary emulsion at about 10,000 rpm; and (d) homogenization of the entire pre-emulsion mixture by applying high shear by homogenizer for about 5 to about 12 cycles.
